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Resumo 
 
Durante o desenvolvimento e progressão do tumor, as células cancerígenas adquirem um 
conjunto de caraterísticas – the hallmarks of cancer –  que contribuem para o crescimento, 
proliferação e invasão do tumor. Uma dessas características reside na capacidade das células 
malignas reprogramarem o seu metabolismo celular. Em 1926, Otto Warburg constatou que, as 
células tumorais adotavam preferencialmente a glicólise em relação à fosforilação oxidativa 
como forma de obtenção de energia mesmo na presença de oxigénio, dando particular 
relevância a esta característica das células tumorais. Este fenómeno, denominado “efeito de 
Warburg” é também conhecido por glicólise aeróbica e é uma característica transversal à 
maioria dos tumores. Desde então, múltiplas adaptações metabólicas têm sido descritas, 
incluindo, por exemplo, a elevada síntese de ácidos gordos e a sobreexpressão de enzimas 
específicos de determinadas vias metabólicas. Além disso, estudos recentes têm demonstrado 
que o “efeito de Warburg” não é uma condição sine qua non de todos os tumores e a fosforilação 
oxidativa assume um papel relevante na agressividade do cancro, nomeadamente num contexto 
de migração e invasão das células tumorais. 
Atualmente, o cancro da mama é o tipo de cancro mais frequente e o segundo mais mortífero 
entre mulheres. Em parte, este problema resulta da enorme complexidade do tumor do ponto 
de vista molecular e morfológico, o que se traduz numa ampla diversidade de situações clínicas 
que, por sua vez, são afetadas pelas caraterísticas biológicas do hospedeiro, contribuindo ainda 
mais para a heterogeneidade tumoral. Existem diversos tipos de cancro da mama, sendo estes 
classificados de acordo com a presença ou ausência de expressão de recetores hormonais de 
estrogénio (ER) e progesterona (PR) e do recetor do fator de crescimento epidérmico 2 (HER2). 
Devido às caraterísticas intrínsecas de maior agressividade e à falta de terapêutica dirigida, o 
cancro da mama triplo-negativo apresenta pior prognóstico comparativamente aos outros 
subtipos. 
O microambiente do tumor assume um papel crucial na progressão do cancro, uma vez que as 
células não-malignas que constituem o estroma tumoral produzem e libertam moléculas que 
podem ter uma função pro-tumoral. A par dos macrófagos e dos fibroblastos, os adipócitos são 
um dos componentes principais do estroma do cancro da mama e existe um importante 
crosstalk entre estes e as células tumorais, através da libertação recíproca de moléculas 
sinalizadoras, metabolitos e citocinas, que favorecem o desenvolvimento da doença. Além disso, 
os adipócitos podem fornecer lípidos às células tumorais que, por sua vez, podem ser utilizados 
como “combustível” para o crescimento e proliferação do tumor. Adicionalmente, a maioria dos 
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tumores apresenta desregulação do metabolismo lipídico, fator que potencializa os efeitos 
anteriormente mencionados, contribuindo para um fenótipo mais agressivo. Os estudos 
epidemiológicos não oferecem dados muito consensuais acerca da associação entre elevados 
níveis de LDL e elevado risco de cancro da mama. Contudo, um estudo recente mostrou que 
determinadas variações genéticas associadas a elevados níveis de colesterol correlacionam-se 
positivamente com risco de cancro da mama. Adicionalmente, o nosso Laboratório mostrou que, 
durante o diagnóstico do cancro da mama, mulheres com elevados níveis de LDL desenvolvem 
tumores maiores e com maior índice proliferativo e,  in vivo, ratos sujeitos a dieta rica em 
colesterol também apresentam estas caraterísticas: tumores maiores e com maior índice 
proliferativo. Observou-se também em estudos in vitro, em ambientes ricos em LDL, o aumento 
da capacidade migratória e proliferativa, bem como a perda de expressão de proteínas 
envolvidas nos mecanismos de adesão celular (caderina, claudina 7 e ocludina, por exemplo) e 
a sobreexpressão de intermediários das vias Akt e ERK, ambas responsáveis por uma resposta 
de sobrevivência. Contudo, os mecanismos moleculares subjacentes à maior agressividade 
tumoral induzida pela exposição a LDL permanecem pouco esclarecidos. 
Além da reprogramação do metabolismo celular, as células tumorais também apresentam 
frequentemente disfunções da dinâmica mitocondrial. As mitocôndrias são organelos versáteis, 
capazes de modelar a sua forma e distribuição na célula, consoante as funções que estão a 
desempenhar e as necessidades da mesma. Relativamente à dinâmica, as mitocôndrias podem 
apresentar-se com uma forma mais oval e alongada, designando-se por “mitocôndrias 
elongadas” ou mais redondas e pequenas denominando-se por “mitocôndrias fragmentadas”. 
O balanço entre mitocôndrias elongadas e fragmentadas é controlado por um processo de 
fissão-fusão, bastante regulado do ponto de vista fisiológico e que se encontra alterado nas 
células tumorais. Por exemplo, as células tumorais apresentam essencialmente uma rede 
mitocondrial mais fragmentada e tal está associado a um fenótipo mais agressivo.  Em relação à 
distribuição celular, a rede mitocondrial pode localizar-se preferencialmente em torno do núcleo 
– rede perinuclear - ou distribuir-se ao longo de toda a célula, sob a forma de longos filamentos 
– rede filamentosa. Neste processo, o citosqueleto com o auxílio de proteínas motoras 
desempenham um importante papel na mobilização da rede mitocondrial ao longo da célula. 
Tendo em conta todos estes aspetos, não é surpreendente que as células tumorais consigam 
reprogramar o metabolismo, a morfologia, a dinâmica e a própria distribuição da rede 
mitocondrial na célula, em função do microambiente que as rodeia e do que é mais favorável 
para o crescimento e proliferação do tumor.  
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A reprogramação do metabolismo lipídico pode estar associada à disfunção mitocondrial, no 
entanto os mecanismos envolvidos na regulação destes dois fatores permanecem pouco 
esclarecidos, nomeadamente no contexto de migração e invasão das células tumorais. 
Outro problema responsável pela elevada taxa de recidiva e de morte em pacientes com cancro, 
é a  aquisição de resistência às terapêuticas. Devido à falta de terapêutica dirigida, em pacientes 
com cancro da mama triplo-negativo este fator encontra-se agravado, uma vez que os pacientes 
estão sujeitos às terapêuticas mais convencionais, nomeadamente à quimioterapia. Estudos 
recentes têm reportado a disfunção mitocondrial e a reprogramação do metabolismo lipídico 
como mecanismos de resistência à quimioterapia em cancro da mama. Deste modo, a 
caraterização dos aspetos morfológicos e moleculares subjacentes à reprogramação metabólica 
e à disfunção mitocondrial envolvidos na resistência à quimioterapia são importantes, pois 
podem contribuir para o desenvolvimento de eventuais terapias dirigidas e desse modo reverter 
a resistência aquirida. 
O presente estudo focou-se na resposta a duas questões principais: por um lado,  pretendeu-se 
compreender de que modo as mitocôndrias se adaptam à exposição a LDL e como é que isso de 
algum modo contribui para um aumento da capacidade migratória em cancro da mama triplo-
negativo; por outro lado, também decidiu-se explorar a influência do papel da exposição crónica 
a um agente quimioterapêutico, nomeadamente o Taxol, no fenótipo de células tumorais de 
cancro da mama triplo-negativo (mais especificamente, na capacidade migratória e proliferativa 
e na massa mitocondrial), bem como se a exposição a LDL também influencia estes parâmetros 
nestas mesmas células. No geral, os nossos resultados sugerem que o fenótipo agressivo 
provocado pela exposição a LDL, em células de cancro de mama triplo-negativo, é acompanhado 
por alterações em diversos parâmetros relacionados com a morfologia e rede mitocondrial. 
Adicionalmente, os nossos resultados mostram que este facto também poderá ser dependente 
de interações específicas entre mitocôndria e citosqueleto. Por sua vez, no contexto de 
resistência à quimioterapia, os dados mostraram que os efeitos produzidos pelo LDL são 
particularmente pronunciados após uma exposição prolongada ao Taxol e não durante o 
tratamento. Assim, este estudo fornece novos conceitos acerca do papel do LDL na 
agressividade do cancro da mama triplo-negativo, incluindo no contexto de resistência à terapia, 
um assunto ainda muito pouco explorado, providenciando, deste modo, potenciais ideias que 
poderão ser relevantes para realização de estudos posteriores e as quais poderão ter interesse 
do ponto de vista clínico. 
 
Palavras-chave: Metabolismo Tumoral, Cancro da Mama Triplo-Negativo, Mitocôndria, LDL, 
Resistência Quimioterapêutica 
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Abstract 
 
Breast cancer remains the most common cancer and the second cause of cancer related death 
among women despite the significant advances in diagnostic and therapy. In one hand, tumors 
display great molecular and morphological heterogeneity; on the other hand, host biological 
characteristics contribute to the wide diversity of clinical situations. During cancer progression, 
tumor cells acquire specific features, designated as the hallmarks of cancer that enable tumor 
growth, proliferation and dissemination, which globally may contribute to escape apoptosis and 
therapeutic intervention. Deregulated cellular energetics is nowadays considered an emerging 
hallmark of cancer. In particular, abnormal lipid metabolism has been reported as one of the 
metabolic adaptations exhibited by tumors, including breast cancer, which allows the 
acquisition of aggressiveness and favors tumor invasion and metastasis. Besides presenting 
deregulated cellular energetics, tumor cells often exhibit mitochondrial dysfunction. 
Reprogramming of lipid metabolism has been associated with mitochondrial dysfunction, but 
the exact nature of the mechanisms underlying this regulation remains poorly understood. 
Resistance to therapy, including chemotherapy, is a major cause of cancer related death. More 
recently, it was described that reprogramming lipid metabolism, as well as mitochondrial 
dysfunction are both involved in the acquisition of resistance to conventional cancer therapy. 
In this study, we aim to unravel how mitochondria adapt in high hypercholesterolemic 
environments (LDL) and if mitochondrial adaptations are required for the acquisition of 
increased migratory and proliferative phenotype of triple-negative breast cancer (TNBC) under 
these conditions. Also, we aim at understanding how chronic exposure to a chemotherapeutic 
agent, Taxol, influences TNBC cells mitochondrial mass and phenotype (migration and 
proliferation capacity) and if LDL exposure could modulate these parameters. Our results 
suggest that LDL-induced aggressiveness is accompanied by adaptations in mitochondrial 
morphology and network arrangement, which could be dependent on specific mitochondria-
cytoskeleton interactions. Regarding response to chemotherapy, our data show that the effects 
produced by LDL exposure are particularly pronounced after prolonged exposure to Taxol and 
not during acute treatment. Overall, this study provides novel mechanistic concepts about the 
impact of LDL exposure in the acquisition of TNBC cells aggressive phenotype, including response 
to chemotherapy, which offer important insights for the development of future studies. 
 
Keywords: Cancer Metabolism, Triple-Negative Breast Cancer, Mitochondria, LDL, Resistance 
to Chemotherapy. 
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1. Introduction 
 
1.1. Breast cancer  
Breast cancer remains the most common cancer and represents the second most frequent 
cause of cancer-related deaths among women. In part, this problem is related to its great 
heterogeneity and complexity at molecular and morphological levels, which translate into a 
diverse clinical entity and is affected by its host biological characteristics 1.  
Breast cancer can be classified according to the expression and/or lack of expression of 
hormone receptors, such as estrogen receptor (ER) and progesterone receptor (PR), as well as 
expression and/or lack of expression of the human epidermal growth factor receptor 2 (HER2). 
Taking into account its gene expression and immunohistochemistry profile, breast cancer can 
be classified in luminal A (ER+, PR+/-, HER2-), luminal B (ER+, PR+/-, HER2+), HER2 (ER-, PR-, 
HER+) and triple-negative (ER-, PR-. HER2-). Among TNBC subtype, it can be further classified 
into basal-like or claudin-low and the latter one represents an even more aggressive subtype 
with worse response to chemotherapy 2.  
Each subtype of breast cancer is associated with a different prognosis and follows different 
therapeutic guidelines. Due to its intrinsic aggressiveness, as well as the lack of targeted 
therapies, TNBC has a poor prognosis when compared to other subtypes of breast cancer 3.  
In order to identify and develop potential candidates for targeted therapy, it is imperative 
to better understand the molecular and morphological mechanisms underlying TNBC 
aggressiveness, as well as the impact of the tumor microenvironment on this subtype of breast 
cancer. 
1.2. Reprogramming cell metabolism in cancer 
In 1926, Otto Warburg first described that cancer cells preferentially adopt glycolysis over 
OXPHOS (oxidative phosphorylation), even in the presence of oxygen 4. In 2011, Hanahan and 
Weinberg proposed a new generation of hallmarks of cancer where deregulated cellular 
energetics emerged as a new hallmark 5. Nowadays the so-called “Warburg Effect” is considered 
a well established feature of most cancers and additionally  several other metabolic adaptations 
that support tumor progression have been described, including increased synthesis of proteins, 
nucleotides and fatty acids 6,7. Moreover, recent studies have shown that OXPHOS and 
mitochondrial respiration play a key role in tumors, especially in tumor migration, invasion and 
therapy-resistance 8–10.  
2 
 
Among other aspects, tumors rely on these metabolic adaptations in order to sustain cell 
growth, proliferation and invasion, escaping apoptosis and becoming resistant to conventional 
therapies, such as chemotherapy. 
1.2.1. Reprogramming lipid metabolism in breast cancer  
Lipids constitute one of the essentials biomolecules to life, performing structural and 
bioenergetic functions in the cell. They include fatty acids (FAs), triacylglycerols (TAGs), sterols 
(like cholesterol), among others 11. The metabolic pathways responsible for lipids biosynthesis 
and degradation are very complex and they require the intervention of several metabolites and 
intermediates, such as signaling molecules, growth factors and chemokines 12–14. A wide variety 
of studies report increased expression and activity of lipogenic enzymes in tumors, namely 
Acetyl-CoA carboxilase (ACC) and fatty acid synthase (FASN), as well as ATP citrate lyase (ACLY) 
that promotes choleterol synthesis 12,15,16. 
Most tumors, including breast cancer, present adaptations and abnormal signaling in 
pathways linked to lipid metabolism. Tumors take advantage of abnormal lipid metabolism in 
order to promote their growth and proliferation, allowing the acquisition of a more aggressive 
phenotype that favor invasion and metastasis 6,11,14,17. 
Cancer cells have the ability to store excessive lipids in lipids droplets (LDs), which are 
small organelles derived from the endoplasmatic reticulum containing TAGs and cholesterol 
which are surrounded by a phospholipid monolayer 18. The high amount of LDs in cancer cells 
has been associated with a more aggressive phenotype. For instance, MDA-MB-231 and MDA-
MB-436, two human TNBC cell lines, have more LDs when compared to MCF-7, a human luminal 
A breast cancer cell line. The same study showed that  in the presence of lipid depleted medium, 
MDA-MB-231 cells exhibit a decrease of LDs content concomitant with a decrease in its 
migratory capacity 19.  
In addition to the energy supply function, lipids also perform structural functions. Beloribi-
Djefalia et al., reviewed among other aspects the importance of lipid rafts in cancer. Lipid rafts 
not only control cell membrane dynamics and transport, but also have a key role in cell signaling. 
In early, advanced and metastatic breast cancer, lipid rafts have the ability to regulate pro-
oncogenic and apoptotic pathways and can interfere with cytoskeleton and focal adhesion 
dynamics, therefore contributing to cancer cell migration and invasion 14. 
Taking into account all these aspects, there is strong evidence that targeting abnormal 
lipid metabolism in cancer could be a promising and innovative strategy to stop cancer cells 
proliferation and dissemination. 
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In 2016, Camarda et al., showed through metabolomic approach that several 
intermediates of fatty acid oxidation (FAO) are upregulated in a genetic-driven model of TNBC 
overexpressing the oncogenic transcription factor MYC (MO-TNBC). The pharmacologic 
inhibition of FAO with etomoxir led to a decrease of metabolic energy of MO-TNBC and 
attenuated tumor growth in vivo 20. Moreover, other studies have reinforced the importance of 
mitochondrial fatty acid β-oxidation as an important energy pathway in metastatic TNBC and 
the effect of oleic acid in promoting breast cancer cells proliferation through CD36 (fatty acid 
translocase) 21. 
Tumor microenvironment plays a critical role in cancer progression since non-malignant 
cells that constitute the tumor stroma can produce and release pro-tumoral molecules. Such as 
macrophages, fibroblasts and endothelial cells, adipocytes are one of the major components of 
breast cancer stroma. There is a strong crosstalk between adipocytes and breast cancer cells 
through the exchange of signaling molecules and metabolites. In one hand, breast cancer cells 
release cytokines and lypophilic enzymes that mediate the establishment of cancer-associated 
adipocytes (CAAs) with particular features, including delipidation, dedifferentiation and 
abnormal secretion. On the other hand, adipocytes release, cytokynes, adipokynes and 
hormones, among other factors, that contribute to a more aggressive phenotype of breast 
cancer cells. Also, adipocytes can provide lipids that are used as fuels to tumor growth and 
proliferation 16. Together, these evidences show the key role of lipid metabolism for cancer 
progression.  
Cholesterol is an essential lipid component in mammalian cellular membranes as it 
assumes crucial functions for life, such as regulating fluidity and being an important component 
of lipid rafts 11. Mammalian cells acquire cholesterol from two different sources: in one hand, 
cells can uptake cholesterol from extracellular lipoproteins (exogenous source) to the 
endoplasmatic reticulum (ER), in a process that could be mediated by Aster, as reviewed in a 
recent study22; on the other hand, cells can acquire cholesterol from de novo synthesis from 
glucose (endogenous synthesis) 23. Breast cancer cells can take advantage on this endogenous 
synthesis and upregulate glycolysis, as well as FASN and HMG-CoA, both enzymes responsible 
for fatty acids and cholesterol synthesis, respectively 19. LDL, also known as low-density 
lipoprotein, is constituted by multiple proteins and variable amounts of several lipids (including 
cholesterol, phospholipids and triglycerides) which is responsible for transporting cholesterol 
from the liver to the tissues 11 (Figure 1).  
Concerning high levels of LDL and increased risk for breast cancer, epidemiological studies 
are not very consensual 24–26. However, it was shown that patients with increased levels of LDL 
at the diagnosis stage, develop larger and more proliferative breast tumors 27.  
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Moreover, a recent study involving more than 400.000 patients showed that genetically raised 
LDL-cholesterol is associated with higher risk for breast cancer 28. 
Cancer cells additionally present increased uptake of exogenous circulating lipids, such as 
LDL. Recently, our lab showed that LDL plays an important role in modulating breast cancer 
progression using both in vitro and in vivo cancer models. LDL exposure promotes epithelial-to-
mesenchymal-transition (EMT) features, increased proliferation and migratory capacity, as well 
as loss of adhesion with decreased expression of adhesion molecules such as cadherin-related 
family member3, claudin 7 and ocludin. Moreover, mice fed with a high-cholesterol diet present 
larger and more proliferative breast tumors and exhibit more often lung metastases, 
Figure 1. Simplified overview of lipid metabolism. 
Mammalian cells acquire cholesterol from two different sources: uptake from extracellular 
lipoproteins (LDL) – exogenous source - or de novo synthesis from glucose – endogenous source. 
Additionally, cholesterol can be exported to the endothelium in the form of lipoproteins (HDL, 
LDL) or can be stored in lipid droplets (LDs). Cancer cells, including breast cancer cells, often 
exhibit deregulated lipid metabolism and present upregulated glycolysis as well as upregulated 
FASN, enzyme responsible for fatty acids synthesis. 
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corroborating with the in vitro data 29. Also, in the clinic, plasma level of LDL can be used as a 
biomarker for breast cancer progression. Breast cancer patients with elevated levels of LDL at 
diagnosis, present larger tumors with higher proliferative rate. Additionally, higher levels of LDL 
are associated with poor disease free survival (DFS) 27. Despite this knowledge, the exact 
mechanisms that mediate LDL-induced aggressiveness in breast cancer progression remain 
unclear.  
Taken together, the presented evidence suggests that targeting lipids, and in particular 
LDL, could be a novel and innovative strategy to prevent breast cancer growth and 
dissemination. A review from Beloribi-Djefalia et al., show a set of ongoing studies, mostly 
preclinical trials, that explore the use of lipogenic enzyme inhibitors as anticancer therapy, 
including statins and etomoxir; reinforcing the emerging importance of lipid metabolism as 
potential targets for anticancer therapy 14. 
1.2.2. Mitochondrial dysfunction in breast cancer 
Mitochondria are dynamic organelles, well known to be the “powerhouse of the cell” since 
they provide most cellular energy, either by generating ATP through OXPHOS or by contributing 
to the synthesis of several metabolites, such as fatty acids and carbohydrates 30. In addition to 
its bioenergetic functions, mitochondria also play an important role in controlling intracellular 
calcium concentration and in apoptosis 31,32. 
Mitochondria perform multiple functions in the cell, so it is essential that they model their 
shape and size, as well as cellular distribution (Figure 2), in order to efficiently meet the cellular 
demands. Regarding mitochondrial dynamics, mitochondria can exhibit tubular and elongated 
networks – elongated mitochondria – or they can appear as fragmented, rounded and 
punctuated structures – fragmented mitochondria. The balance between elongated and 
fragmented mitochondria is controlled by a fission/fusion process, which in turn is regulated by 
dynamin related GTPases, in a highly conserved process. After undergoing post-translational 
modification, Drp1 is recruited by mitochondria, promoting mitochondrial fragmentation and 
mediating the fission process, whereas Mfn1 and Mfn2 are responsible for mediating the fusion 
process of the mitochondrial outer membrane 33. 
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Mitochondria are also able to model their cellular distribution, depending on the cell type 
and energy demands. They may lie more around the nucleus - perinuclear mitochondrial 
network – or distribute throughout the cell in long filaments – filamentous mitochondrial 
network 34. The cellular distribution of mitochondria in the cell requires an interaction with the 
cytoskeleton, including microtubules or actin filaments. This interaction also requires the 
participation of motor proteins, such as myosin that assists movement through actin filaments 
and dinein and kinesin, which help in the movement through the microtubules35. 
 Mitochondria play a key role in cancer and its dysfunction is present in breast cancer, providing 
a wide diversity of advantages to the tumor cell. Cancer cells are able to reprogram their cellular 
metabolism in order to sustain their proliferation and growth and they can also regulate 
Figure 2. Schematic (simplified) representation of mitochondrial dynamics and mitochondrial 
network distribution. 
Mitochondria modulate their shape and size through a stricktly regulated fusion/fission process. 
Fusion induces more elongated mitochondria and it is mediated by Mfn 1/2, whereas fission 
increases mitochondria fragmentation and it is mediated by Drp1. Mitochondria can also exhibit 
different subcellular distribution, according to specific cell needs, could  appearing more 
perinuclear or more filamentous arranged throughout the whole cell. 
 
7 
 
mitochondrial dynamics according to what favors tumor the most. Additionally, mitochondria 
may also take advantage of the interaction with cytoskeleton and be mobilized to certain regions 
of the cell that facilitates invasion and migration processes.  
In cancer, the interaction between mitochondria and the cytoskeleton has an important 
role. As motor proteins regulate and drive mitochondria distribution to sites of high-energy 
demand, this can provide an advantage to tumor cells in certain processes, such as migration 
and invasion. Indeed, in MDA-MB-231 cells, the accumulation of mitochondria in the leading 
edge is concomitant with a higher velocity of migration 36. 
Mitochondrial dysfunction is associated with deregulated cellular energetics and this 
includes not only adaptations of mitochondrial metabolism, but also changes in mitochondrial 
dynamics, cellular distribution and mitochondrial DNA content 30,33,37. For instance, 
mitochondria are more fragmented in metastatic breast cancer and Drp1 expression is increased 
in human invasive breast carcinomas 31. Also, circulating tumor cells exhibit a higher 
mitochondrial DNA content when compared to primary cancer cells, suggesting that cancer cells 
can remodel mitochondria mass and number in a way that most efficiently favors its progression 
within a particular environment 9. Recently,  a study described a molecular mechanism in which 
ACC1, a lipogenic enzyme involved in the regulation of de novo FA synthesis, contributes to the 
increase of mitochondrial fission in pluripotent stem cells 38, providing a mechanistic link 
between lipid metabolism and regulation of mitochondrial dynamics.  
Together, these facts suggest that understanding the molecular mechanisms underlying 
mitochondrial network distribution and its specific interaction with lipidic metabolism and the 
cytoskeleton could be a promising approach to find new potential targets for anticancer therapy. 
1.3. Chemotherapy resistance in breast cancer 
Depending on the breast cancer subtype and the stage of disease progression (early, 
advanced or metastatic), there is a wide variety of therapies available for treatment. 
Chemotherapy is used as first line therapy for metastatic breast cancer (MBC) or for patients 
with TNBC. It is used as adjuvant therapy for patients with MBC that already received local 
treatment (like surgery, for instance) and have a high risk of relapse. The most common 
chemotherapeutic agents used in breast cancer treatment include antracyclines, taxanes, 
gemcitabine, vinorelbine and carboplatin 1,3,39,40. 
Despite significantly improvement in anti-cancer therapy, one of the leading causes of 
cancer-related death in breast cancer is the acquisition of therapy resistance, including to 
chemotherapy. The lack of targeted therapy for TNBC reduces the therapeutic options for breast 
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cancer subtype, increasing tumor recurrence associated with resistance to therapy, with 
development of metastases, cancer spread and worse prognosis 3. 
Taxol, also known as paclitaxel, is a microtubule-stabilizing drug belonging to the Taxanes 
family,  widely used as chemotherapeutic agent approved (by FDA) for the treatment of ovarian 
and breast cancer and, in particular it is used as first line therapy for the treatment of MBC 39,41,42. 
Microtubules consist of long protein polymers composed of repeating subunits of α- and β-
tubulin which are responsible for important cellular functions, such as cell division, motility, cell 
shape and signaling 40. The mechanism of Taxol action lies in the ability to interact with 
microtubules and interfere with its dynamics of polymerization and depolymerization events, 
which is essential to cell division and chromosome segregation during mitosis. Taxol binds to 
Taxol-binding site located in the luminal side of β-tubulin subunit and induces mitotic arrest. 
Consequently, the metaphase-anaphase transition is inhibited, mitosis is blocked and most cells 
enter in apoptosis. In some cases, cells can exit mitosis through mitotic slippage, without 
needing anaphase or cytokinesis. This phenomenon is characterized by producing tetraploid and 
multinucleated G1 cells that did not undergo chromosomal segregation 40,41,43. Due to its ability 
to interfere with microtubules dynamics, Taxol is also used commonly used in biomedical 
research as a cytoskeleton-destabilizing agent 44–46 . 
As for other agents, treatment with Taxol eventually leads to the acquisition of resistance 
by the tumor cells. McGrogan et al., reviewed some mechanisms associated with acquired 
resistance to Taxol which include mutations in α- and β- subunits that weaken the binding with 
Taxol and overexpression of P-glycoprotein (P-gp), responsible for the efflux of several drugs 
leading to decreased intracellular levels and drug resistance 40.  
Thus, it is essential to understand the diversity of molecular mechanisms underlying 
acquired resistance to chemotherapy in order to develop strategies that counteract this 
phenomenon and re-sensitize cancer cells to therapy.  
1.3.1. Metabolic adaptations in chemotherapy resistant (breast) cancer  
Lately, reprogramming cell metabolism in tumor cells has been pointed out as one of the 
features which tumor cells commonly adapt in order to acquire resistance to chemotherapy 47.  
The acquired resistance to anti-cancer therapies, including chemotherapy, is often 
associated to a special population of cancer cells that survives to therapeutic intervention. This 
cell population is known in the clinics as minimal residual disease (MRD). Recently, a study in 
mice mimicking MRD reveal that residual breast cancer cells have a defined metabolic signature 
and a transcriptome distinct from the normal epithelial cells and the primary breast tumor. Also, 
this study revealed that the population of cells with acquired resistance to therapeutic 
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intervention present altered lipid metabolism and higher production of reactive oxygen species 
(ROS) 13. 
Additional studies have reported that reprogramming of lipid metabolism is one of the 
causes of resistance to chemotherapy. For instance, JAK/STAT3 pathway induces fatty acids β-
oxidation (FAO) through the transcription of CPT1B, a crucial enzyme of FAO, which in turn 
promotes breast cancer stem cells (BCSCs) self-renewal and chemotherapy resistance. 
Additionally, leptin derived from mammary-adipocytes upregulates JAK/STAT3 pathway, further 
enhancing this effect. Through the inhibition of FAO or leptin, it is possible to inhibit BCSCs and 
reverse the chemo resistant phenotype 48. 
High amounts of LDs are also associated with increase resistance to chemotherapy. It was 
shown that pancreatic ductal adenocarcinoma (PDAC) presents increased amounts of 
cholesterol, as well as overexpression of LDL receptor (LDLR) and inhibition of cholesterol uptake 
resensitized cells to chemotherapy, contributing to PDAC regression 49 . 
Mitochondrial dysfunction is also associated with increased resistance to chemotherapy. 
MYC and MCL1, a proto-oncogene and a pro-apoptotic protein of Bcl-2 family respectively, are 
co-amplified in chemotherapy resistant TNBC. Together, they contribute to increase OXPHOS 
and ROS levels, both processes involved in the maintenance of CSCs. In turn, the higher levels of 
OXPHOS contribute to accumulation of HIF1α and blocking HIF1α was shown to decrease CSCs 
enrichment, decreasing resistance to chemotherapy and attenuating tumor growth in vivo 10 
Specifically regarding Taxol, several studies have suggested that targeting the metabolism 
of tumor cells is a strategy to reverse chemotherapy resistance in different tumor types 50.  In 
breast cancer, human MDA-MB-435 cells with high LDH-A expression can be resensitized to 
Taxol either through the use of siRNA that downregulates LDH-A expression or using oxamate, 
a LDH-A inhibitor 51. A similar study, showed increased expression of glutaminase 1 (GLS1) in 
Taxol-resistant MDA-MB-231 cells. Downregulation of GLS1 using siRNA resensitized MDA-MB-
231 cells to Taxol whereas overexpression of GLS1 in BT-474, a Taxol-sensitive BC cell line, 
rendered the cells resistant 52. 
In summary, abnormal cell metabolism and mitochondrial dysfunction play a key role in 
chemotherapy resistance, a major cause of breast cancer-related death. Therefore, it is crucial 
to characterize the resistant phenotypes and to discover new molecular mechanisms involved 
in acquired resistance to chemotherapy with the aim of developing alternative strategies to 
counteract chemotherapy resistance in breast cancer. 
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2. Aims 
 
TNBC cells are able to reprogram their cellular metabolism in order to sustain tumor growth 
and progression. Recent data from our laboratory showed that exposure to LDL-enriched 
environments is accompanied by alterations in mitochondrial mass and dynamics, which could 
be at the basis of the increased migratory and proliferative phenotype displayed by LDL-exposed 
cells. Despite this knowledge, the exact molecular implications of the altered mitochondria 
morphology/network for LDL-induced TNBC aggressiveness remained unclear. Additionally, 
dysfunction in lipid metabolism and in mitochondrial metabolism and morphology have been 
reported as one of the main causes of chemotherapy resistance.  
Therefore, the aim of this thesis is to study the following two main hypothesis: 
• How mitochondria adapt to LDL exposure and how this contributes for the aggressive 
migratory phenotype in TNBC? Is this process mediated by the cytoskeleton? 
• How chronic exposure to the chemotherapeutic agent Taxol influences the phenotypic 
properties of TNBC cells (namely, migratory and proliferative capacities) and 
additionally, the mitochondria mass? Moreover, does LDL exposure influence all these 
features in Taxol acute or chronically-exposed TNBC cells? 
Therefore, the specific aims of this study/thesis are: 
• Aim 1. Characterization of the mitochondrial morphology in LDL-exposed migrating 
MDA-MB-231 cells.  
• Aim 2. Determination of the role of cytoskeleton in mitochondrial morphology in LDL-
exposed migrating MDA-MB-231 cells.  
• Aim 3. Establishment of Taxol-resistant TNBC cell lines (MDA-MB-231 and/or MDA-MB-
468) in vitro.  
• Aim 4. Determination of the role of LDL in Taxol-resistant TNBC cell lines.  
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3. Materials and Methods 
 
3.1. Cell Culture 
MDA-MB-231, MDA-MB-468, BT-474 and MCF-7 human breast cancer cell lines were cultured 
in DMEM (Thermo Fisher Scientific) supplemented with 10% (v/v) heat-inactivated FBS (Gibco 
Invitrogen) and 1% Antibiotic-Antimycotic (Gibco Invitrogen), named complete DMEM and 
incubated at 37ºC and 5% CO2 atmosphere. 
3.1.1. Generation of Taxol-resistant breast cancer cell lines 
MDA-MB-231 and MDA-MB-468 cells were cultured in flat bottom 6-wells plates, in complete 
DMEM and permanently treated with Taxol (Sigma) at a final concentration of 2,5 nM, during 3 
months. After this period, it was performed a viability assay to evaluate the sensitivity to Taxol 
between the parental and chronically exposed (CE) cell lines. For the subsequent experiments, 
the MDA-MB-231 CE-Taxol cell line was treated with Taxol 2,5 nM to maintain Taxol resistance. 
3.1.2. Mito-YFP transfection 
MDA-MB-231 cells were seeded at a density of 2x105 cells/mL in 35 mm glass bottom dishes and 
after 24 hours transfected with 2 μg Mito-YFP using FuGENE (ThermoFisher Scientific) and 
according to the manufacturer instructions.  
3.2. Viability Assays 
To test the sensitivity of cancer cells lines to Taxol, cells were seeded at a density of 1 x 105 
cells/mL in a flat-bottom 24 well-plate and subjected to different Taxol concentrations (0; 1; 2,5; 
5; 7,5 and 10 nM). After 5 days, the number of viable cells was determined using Trypan Blue 
exclusion test by hemocytometer counts (4 squares per well), in quadruplicates. To test the 
effect of LDL in the response to Taxol, cancer cells lines were seeded at a density of 4 x 104 
cells/mL in a flat bottom 24 well-plate, in complete DMEM. After 24h, the medium was replaced 
by DMEM 1% FBS-LPF for 24h. After this period, medium was replaced by fresh DMEM with 1% 
FBS-LPF only or supplemented with LDL 100 μg/mL (Merck) or Taxol 2,5 nM alone or in 
combination for 48h. The number of viable cells was determined using Trypan Blue exclusion 
test by hemocytometer counts (4 squares per well), in quadruplicates. 
3.3. Proliferation Assays 
Cancer cell lines were seeded at a density of 4 x 104 cells/mL in a flat bottom 24 well-plate, in 
complete DMEM. After 24h, the medium was replaced by DMEM supplemented with 1% (v/v) 
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FBS-LPF (fetal bovine serum – lipoprotein free) (Bio West) for 24h. After this period, medium 
was replaced by fresh DMEM with 1% FBS-LPF only or supplemented with LDL 100 μg/mL 
(Merck) or Taxol 2,5 nM alone or in combination for 48h. The number of viable cells was 
determined using Trypan Blue exclusion test by hemocytometer counts (4 squares per well), in 
quadruplicates. 
3.4. Wound-Healing Assay 
MDA-MB-231 cells were seeded at a density of 1,5 x 105 cells/mL in a flat bottom 24-well plates 
in 500 μL complete DMEM. After 48h, when cells reached confluence, the medium was replaced 
by DMEM supplemented with 1% (v/v) FBS-LPF for 24h. Blue tips (1000 μL) were used to make 
a scratch (“wound”) in the center of the wells. Cells were washed with PBS 1x and the medium 
was replaced by fresh DMEM with 1% FBS-LPF, supplemented with Mitomycin C (Merck 
Milipore; 0,5 μM) only or supplemented with LDL 100 μg/mL or Taxol (20 nM  or 2,5 nM) or LPA 
(Sigma-Aldrich, 10 μM) alone or in combination. Cells were allowed to migrate during 16h 
(assays with LDL and LPA or with LDL,Taxol 2,5 nM, LDL+Taxol 2,5 nM) or 24h (assays with LDL, 
Taxol 20 nM, LDL + Taxol 20 nM) and at least two photos per well were taken at starting and 
ending time in a Zeiss Primovert microscope (4x objective) coupled with a Zeiss AxioCam ERc 5s 
camara. Cell migration distance was measured by subtracting the wound length at the final time 
from the initial time, using Fiji software (10 measurements per well in triplicates). 
3.5. mtDNA determination 
For mtDNA determination, total DNA was isolated from cells using phenol:chloroform:isoamyl 
alcohol (Sigma) and measured by assessing the levels of the human mitochondrial NADH 
dehydrogenase 1 (ND1) relative to nuclear β2-microglobulin (B2MG) gene. qPCR was performed 
using iTaq Universal SYBR Green Supermix (Bio-Rad), following manufacturer procedures, in an 
Applied Biosystems ViiA 7 system.  
Primer sequences are described in Table 1. Quantifications were made applying the ∆Ct method 
(Ct of nuclear DNA gene – Ct of mitochondrial DNA gene), followed 2x2^(∆Ct) according to 
Rooney et al.. 53. 
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Table 1. Amplified genes and primers used for mtDNA content quantification using qPCR. 
 
3.6. Flow Cytometry 
For MitoTracker Deep Red (Molecular Probes) staining, cancer cell lines were seeded at a density 
of 3 x 105  cells/mL in flat-bottom 6 well- plates. When cells reached confluence, cells were 
trypsinized, centrifuged at 1000 rpm , washed with PBS 1x and MitoTracker Deep Red (2 nM) 
was added in PBS 1x, during 15 minutes – RT. Cells were washed and ressuspended in PBS 1x. 
For cell death detection, cells were washed in PBS 1x and resuspended in 300 µL of Annexin V-
binding buffer (BD Biosciences) containing 5 mL of 7-aminoactinomycin (7-AAD) (BD 
Pharmingen) and 5 µL of Annexin V-PE (BD Biosciences), and incubated for 15 minutes at RT. 
Flow cytometry analysis was performed in in a LSR Fortessa (BD Biosciences) flow cytometer 
followed by data analysis using the Flow Jo Software. 
3.7. Immunofluorescence 
Cells were seeded in glass coverslips and after culturing, cells were fixed with 4% PFA – 10 
minutes, following by permeabilization with 0,5% Triton X-100 – 5 minutes and blocking with 
0,5% BSA – PBS – 30 minutes. Cells were immunostained with primary antibody (rat anti-human 
α-tubulin YL 1/2, at  1:100; mouse anti-human HSP60, BD Biosciences; at 1:250) overnight. On 
the next day, cells were washed with PBS 1x and incubated with the secondary antibody (goat 
anti-rat Alexa 594, Invitrogen, at 1:500; donkey anti-mouse Alexa 594,  Invitrogen; at 1:500) 
and/or Alexa Fluor Phalloidin 647 (ThermoFisher Scientific, 1:200) for 1h, at RT. Mounting was 
performed using Vectashield with DAPI mounting medium. 
Epifluorescence microscopy was performed in a Zeiss Axiovert 200M microscope and the images 
were acquired with a 63x oil objective. Confocal microscopy was performed in a Zeiss LSM 880 
microscope and the images were acquired with a 63x oil objective (with 1.6x zoom). The images 
were processed using Fiji software. Mitochondrial morphological parameters - mean number of 
mitochondria, mean size of mitochondria, mean interconnectivity, mean interconnectivity with 
correction factor (ratio between the average area and perimeter of mitochondria normalized to 
Gene name Genome Primer Sequence 
Β2MG Nuclear 
Forward  Seq 5′-3′ TCGCTCCGTGGCCTTAGCTGT 
Reverse Seq 5′-3′ CTTTGGAGTACGCTGGATAGCCTCC 
ND1 mitochondrial 
Forward  Seq 5′-3′ CCCTAAAACCCGCCACATCT 
Reverse Seq 5′-3′ GAGCGATGGTGAGAGCTAAGGT 
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their circularity) and mean elongation -, also designated as mitochondrial morphometrics, were 
quantified using Fiji software as previously reported 54. 
3.8. Statistical Analysis 
The results are expressed as a mean ± s.d. and analyzed using unpaired Student’s two-tailed t-
test (* P < 0,05; ** P < 0,01; *** P < 0,001). 
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4. Results 
 
4.1. Role of LDL in the mitochondrial mass and network morphology of migrating 
TNBC cells 
 
Previous studies have shown that LDL plays a key role in the aggressiveness of breast 
cancer, especially in the triple-negative subtype 19,27,29. Preliminary results from our lab revealed 
that LDL exposure of TNBC cell is accompanied by an increase in the mitochondrial mass as 
determined by mtDNA content, MitoTracker staining and electron microscopy (Nóbrega-Pereira 
et al., unpublished). However, whether LDL-induced TNBC cells aggressiveness was due to 
mitochondrial metabolic adaptations as well as changes in mitochondrial dynamics, remained 
unclear and was addressed in this thesis.  
In order to answer this question, we investigated a possible association between cell 
migration capacity and mitochondrial mass, and if this effect is exclusive for LDL or more broadly 
applies to other chemotaxis-inducing agents (capable of inducing cell migration). To do this, we 
exposed the human TNBC cell line MDA-MB-231 to LDL or lysophosphatidic acid (LPA),  a potent 
chemoattractant reported as a cell migration inducer of several types of cancer cells, including 
TNBC 55 and performed a wound healing assay, followed by quantification of the mitochondrial 
mass by qPCR. 
When MDA-MB-231 cells were exposed to LPA, there was a significant increase in the 
migratory capacity compared to control or LDL-exposed cells (Figure 3a) and 3b)), however, this 
was not accompanied by a significant increase in the mitochondrial mass (Figure 3c)). These 
results suggest that the increase in mitochondrial mass of LDL-exposed MDA-MB-231 migrating 
cells may be specific to lipid-enriched signals and not to other chemotaxis-inducing agents. 
Indeed, preliminary data suggest that MDA-MB-231 cells exposed to palmitic acid (PA) have an 
increase in the migratory capacity, which is also accompanied by an increase in the 
mitochondrial mass (Supplementary Figure 1). 
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Figure 3. Effect of LDL and LPA in the migratory capacity and mitochondrial mass of MDA-
MB-231 cells. 
a) Migratory capacity represented as percentage of wound closure at 18h by wound 
healing assay (n=4/each from two independent experiments); b) Representative images 
of wound closure at 0h and 18h by optical microscopy (4x objective); c) Relative mtDNA 
content based on the mitochondrial ND1 gene relative to the nuclear gene B2MG in LDL 
and LPA-exposed groups relative to the control group (n = 5/each from two independent 
experiments). Data are presented as mean ± s.d. Statistical significance was determined 
by two-tailed Student t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Taking into account these results and the knowledge that mitochondria are able to 
regulate their shape and structure in function of the microenvironment 30,33,34 we decided to 
analyze the mitochondrial network in migrating MDA-MB-231 under control or upon LDL-
exposure by performing the wound-healing assay followed by immunofluorescence detection 
of the mitochondrial protein HSP60 using confocal microscopy.  
We could observe two different phenotypes of mitochondrial network distribution:  
mitochondrial aggregates (clusters) around the nucleus, often located at only one side and 
designated perinuclear mitochondria (Figure 4a), upper panel) and long mitochondrial 
filaments, located unilaterally or bilaterally around the nucleus and distributed throughout the 
whole cell, designated as filamentous mitochondrial (Figure 4a), lower panel) 56. Based on this 
observation, we decided to qualitatively analyze the type of mitochondrial network distribution 
between control and LDL-exposed MDA-MB-231 cells. We could observe that control MDA-MB-
231 cells display only one phenotype, perinuclear mitochondria, while in the LDL-exposed cells 
the two phenotypes are observed, with approximately 40% filamentous and 60% perinuclear 
mitochondria cellular distribution (Figure 4b)). 
 Some studies relate perinuclear mitochondrial clustering to cell apoptosis 57,58, but 
unpublished data from Nóbrega-Pereira et al., revealed that there is no significant differences 
in apoptosis levels between control and LDL-exposed MDA-MB-231 cells, as determined by 
AnnexinV-7AAD staining. However, it is important to note that MDA-MB-231 cells under control 
conditions are cultured in lipid-depleted medium for 48h and this condition may affect 
mitochondrial network arrangement, since these organelles are very sensitive to changes in 
environment conditions, including changes in nutrients and oxygen availability33. As accessed 
for the mitochondrial mass with mtDNA content evaluation, it will be important to discern 
weather the effects of LDL in mitochondrial network distribution are unique or also present upon 
stimuli with other chemotaxis agents with lipidic (PA) or unrelated nature (such as LPA). 
These results raised the possibility that LDL may regulate the shape and/or mitochondrial 
distribution in migrating cells which may have implications in the increased migratory capacity 
induced by LDL in TNBC cells. 
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Figure 4. Effect of LDL in the mitochondrial network distribution of MDA-MB-231 migrating 
cells. 
a) Representative confocal images of control (upper panel) and LDL-exposed (lower panel) 
MDA-MB-231 cells stained with HSP60 (mitochondria) and DAPI (nuclei). Scale bar equals 10 
μm. b) Qualitative quantification of the % of mitochondria network distribution in migrating 
MDA-MB-231 cells (filamentous versus perinuclear; n=20/21 cells from control and LDL, 
respectively). 
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In order to obtain a more complete analysis of the mitochondrial network, including 
insights into mitochondrial dynamics, we perform a quantitative analysis of the parameters of 
mitochondrial morphology as previously reported by Wiemerslage and Lee 54. The parameters 
of mitochondrial morphology, also known as mitochondrial morphometrics, were quantified 
using a macro developed by Ruben Dagda 59 for ImageJ software. This include the mean number 
and mean size of mitochondria, the interconnectivity (which describes the physical connections 
between mitochondria) and elongation, which describes the shape of mitochondria (a higher 
score for elongation means a higher level of fused mitochondria). On the interconnectivity 
parameter, we also introduced a correction factor to overcome the possibility of mitochondrial 
swelling, often observed in pathological conditions. Taken together, these parameters give an 
overview of the mitochondrial network distribution.  
Thus, we quantified the mitochondrial morphometric parameters in MDA-MB-231 
control or LDL-exposed after perform the wound-healing assay. In a study carried out by Zhao 
et al., the luminal-A breast cancer cell line MCF-7 presents larger mitochondria and increased 
mitochondrial length when compared to TNBC cell lines 31, therefore, we used the MCF-7 cell 
line as a control for the quantification method. Indeed, we were able to reproduce the published 
findings as we detected increase mitochondrial area in MCF-7 cells when compared to MDA-
MB-231 cells (Supplementary Figure 2), as well as increased mitochondrial mass, which was also 
corroborated by us using MitoTracker staining (Supplementary Figure 3).  
Concerning MDA-MB-231 cells, LDL-exposed cells have significantly more and larger 
mitochondria when compared to the control group (Figure 5a) and 5b)). The interconnectivity 
parameter is also significantly altered between both conditions, with LDL-exposed MDA-MB-231 
cells presenting approximately a 12-fold increase compared to control cells (Figure 5c)). As 
previously mentioned, interconnectivity describes the physical connections between 
mitochondria and is often associated with higher levels of fused mitochondria and, consequently 
less fragmented mitochondria. However, the elongation score obtained for LDL-exposed MDA-
MB-231 cells does not support this statement.  
According to Wiemerslage and Lee, if the elongation score is closer to 1, the 
mitochondria will be more circular and consequently the network will be more fragmented and, 
consequently, the less elongated; on the other hand values much higher than 1 describe 
mitochondria with a more abstract and elongated shape. 54 For MCF-7 and control and LDL-MDA-
MB-231 cells, the elongation scores are all close to 1 and there are no significant differences 
among them (Figure 5d) and Supplementary Figure 2), which means that luminal A and TNBC 
cells exhibit fragmented mitochondria. This result is in line with previously reported data in 
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several cancer types, which often exhibit higher levels of mitochondria fragmentation due to 
increase expression of Drp1 and/or downregulation of Mfn2. 
 
 
This quantitative analysis reveal similar results to other analytical techniques regarding 
mitochondria number (MitoTracker, mtDNA content), but inconsistent results in other 
parameters, namely the link between elevated mitochondrial interconnectivity and a higher 
fragmented network, which highlight the necessity of using several alternative quantitative 
Figure 5. Effect of LDL in mitochondrial morphometrics in MDA-MB-231 migrating cells. 
Quantification of mitochondrial morphometrics of Control and LDL-exposed MDA-MB-231 
migrating cells (n ≥ 18 cells). a) Mean number of mitochondria; b) Mean size of mitochondria; 
c) Mean interconnectivity of mitochondria; d) Mean elongation of mitochondria. Data are 
presented as mean ± s.d. Statistical significance was determined by two-tailed Student t-test. 
**, P < 0.01; ***, P < 0.001 
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assays in order to have a more accurate determination of mitochondrial network dynamics and 
distribution across the cells. 
In summary, this analysis revealed that LDL exposure influences the mitochondrial 
network morphology of MDA-MB-231 cells, namely increasing the number and size, as well as 
the physical connections established between mitochondria. On the other hand, LDL seams not 
to influence the elongation parameter which suggests that mitochondrial dynamics may not be 
altered. 
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4.2. Effect of LDL exposure in TNBC migrating cells under acute exposure to Taxol 
 
Our results suggest that LDL-induced aggressiveness in TNBC cells, namely increased 
migratory capacity, is accompanied by alterations in the mitochondrial network (increased 
mitochondrial number, size, interconnectivity and filamentous distribution), therefore, we 
hypothesized that these alterations could impact the interaction between mitochondria and the 
cytoskeleton in migrating TNBC cells. In order to explore this possibility, we decided to disrupt 
the cytoskeleton dynamics using Taxol, a commonly used chemotherapeutic agent of the Taxane 
family. The mechanism of action of Taxol lies in the ability to stabilize microtubules and interfere 
in the dynamics of depolymerization and polymerization, consequently blocking mitosis and 
inducing apoptosis 40. In addition, another effect reported by the action of Taxol is the formation 
of multinucleated cells, consisting of small nuclei resulting from mitotic chromosome 
segregation errors 41,60.  
In order to evaluate the impact of LDL exposure in the effect of acute exposure to Taxol, 
we exposed MDA-MB-231 cells to Taxol alone (20 nM) or in combination with LDL and evaluated 
the number of binucleated and multinucleated cells. In Taxol-exposed MDA-MB-231 cells, the 
percentage of binucleated and multinucleated cells was about 20% and 40% (± s.d.), respectively 
(Figure 6a) middle image and 6b)). On the other hand, adding LDL in combination with Taxol 
lead to a reduction (although non-significant) on the percentage of binucleated and 
multinucleated MDA-MB-231 cells to about 12% and 23%, respectively (± s.d.) (Figure 6a) lower 
image and 6b)). Additionally, the regions of hyperpolymerized α-tubulin (regions with greater 
intensity of pixels) observed in Taxol exposed MDA-MB-231 cells (Figure 6a) middle image) 
where reduced when Taxol was combined to LDL. No significant alterations were observed in 
MDA-MB-231 control (Figure 6a) upper) or LDL-only exposed cells (data not shown). 
For a more accurate analysis of the Taxol effect in MDA-MB-231 cells, we performed a 
cell death assay using AnnexinV-7AAD staining (Figure 6c)). When compared to the control 
condition, we could observe that LDL did not produced any effect, whereas Taxol significantly 
increased cell death. Moreover, when MDA-MB-231 were simultaneously exposed to Taxol and 
LDL, we could observe a rescue of the cell death, significantly lower regarding Taxol condition, 
but still significantly higher when compared to the control group. 
Overall, we can conclude that the acute exposure to the cytoskeleton-destabilizing 
agent Taxol (at 20 nM) significantly increases cell death in Taxol-exposed MDA-MB-231 cells and 
compromises the cellular functional integrity, providing the desired effect for the subsequent 
experiments. 
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Figure 6. Effect of Taxol acute treatment alone and combined to LDL exposure in MDA-MB-
231 cells. 
a) Representative epifluorescence images of Control (upper image), Taxol 20 nM (middle image) 
and Taxol 20 nM + LDL exposed (lower image) of MDA-MB-231 cells stained with α-tubulin in 
red and DAPI (nuclei) in dark blue. White arrows indicate regions of higher pixel intensity that 
represent hyperpolymerized α-tubulin. Images were acquired with a 63x oil objective. Scale bar 
equals 10 μm. b) Percentage of binucleated and multinucleated MDA-MB-231 cells in the 
depicted conditions (n ≥ 100 cells each). Control and LDL-exposed MDA-MB-231 cells are not 
represented because they do not have bi and/or multinucleated cells. c) Cell death of MDA-MB-
231 cells in the depicted conditions. Cell death assayed with AnnexinV-PE-7AAD staining by flow 
cytometry and analyzed using FlowJo software (n = 3 each). Data are presented as mean ± s.d. 
Statistical significance was determined by two-tailed Student t-test. *, P < 0.05; **, P < 0.01. 
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Next, we focused on our hypothesis, if the increased aggressiveness induced by LDL-
exposure in MDA-MB-231 cells was mediated by specific interactions between the 
mitochondrial network and the cytoskeleton. To explore this question, we exposed MDA-MB-
231 cells to LDL, Taxol (20 nM) or both and performed the wound-healing assay followed by 
quantification of the mitochondrial mass. We observed a significant decrease in the migratory 
capacity of MDA-MB-231 cells exposed to Taxol compared to the control group, whereas 
addition of LDL was able to revert the defect in the migratory capacity of Taxol-exposed MDA-
MB-231 cells (Figure 7a) and 7b)). The same trend is observed in the mitochondrial mass 
evaluated by qPCR of mtDNA content, where we could detect a significant decrease in the 
mitochondrial mass of Taxol-exposed MDA-MB-231 cells which was restored in the combined 
treatment of Taxol and LDL (Figure 7c)).  
In order to more accurately determine the effect of Taxol treatment alone or in 
combination with LDL in the mitochondrial network distribution in MDA-MB-231 migrating cells, 
we performed the same quantification as before (Figure 4b)). For that, we exposed MDA-MB-
231 cells to LDL, Taxol and both conditions and performed the wound-healing assay followed by 
immunofluorescence detection of HSP60.  
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Figure 7. LDL reverts the migratory capacity and restores mitochondrial mass of MDA-MB-
231 migrating cells upon acute exposure of Taxol. 
a) Migratory capacity represented as percentage of wound closure at 24h by wound 
healing assay (n = 3/4 each) b) Representative images of wound closure at 0h and 24h 
by optical microscopy (4x objective) c) Relative mtDNA content based on the 
mitochondrial ND1 gene relative to the nuclear gene B2MG (n = 5/6 from two 
independent experiments. Data are presented as mean ± s.d. Statistical significance was 
determined by two-tailed Student t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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As previously shown (Figure 4b)), in MDA-MB-231 cells from the Control group, the 
perinuclear mitochondria phenotype is predominantly present (Figure 8a) upper panel and 8b)) 
while in the MDA-MB-231 LDL-exposed cells, we observe both phenotypes with 55% perinuclear 
and 45% filamentous mitochondria distribution (Figure 8a) second panel and 8b)). In regard to 
Taxol-exposed cells, it is mostly observed the perinuclear mitochondria network phenotype, just 
like in the control condition, although there is a slight decrease in the percentage of perinuclear 
mitochondria and a tenuous increase in the percentage of filamentous mitochondria. Moreover, 
when compared to LDL-exposed group, the Taxol-exposed cells exhibit a decrease in the 
percentage of filamentous mitochondria (around 20%) and an increase in perinuclear 
mitochondria (around 80%) (Figure 8a) third panel and 8b)). Combined exposure of MDA-MB-
231 cells to Taxol and LDL produced an increase in the percentage of filamentous mitochondria 
network distribution (approximately 65%) and a decrease in the percentage of perinuclear 
mitochondria to around 35% (Figure 8a) lower panel and 8b)), when compared to the Taxol 
Figure 8. LDL reverts the phenotype induced by acute Taxol treatment in MDA-MB-231 
migrating cells. 
a) Representative epifluorescence images of Control (upper panel), LDL (second panel), 
Taxol 20 nM (third panel) and Taxol 20 nM+LDL exposed MDA-MB-231 cells (lower panel). Left 
column: HSP60 (mitochondria), right column: merge, HSP60 (mitochondria) and DAPI (nuclei). 
The dashed white line represents the wound front edge. Images were acquired with a 63x oil 
objective. Scale bar equals 10 μm. b) Qualitative quantification of mitochondria network 
distribution (filamentous versus perinuclear) (n=30/31 cells/each).  
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condition. Thus, exposure of MDA-MB-231 cells to LDL was able to rescue the mitochondrial 
network distribution phenotype induced by Taxol, resembling the LDL-condition.  
Overall, these results suggest, firstly, that cytoskeleton-destabilizing agent (in this case, 
Taxol) severely affect the migration of MDA-MB-231 that additionally display decreased 
mitochondrial mass (evaluated by mtDNA content) and disturbance of the mitochondrial 
network distribution; overall highlighting the importance of mitochondrial-cytoskeleton 
interactions in the migratory process of MDA-MB-231 cells. Moreover, we show that LDL is able 
to restore the defects in migratory capacity, mitochondrial mass (as evaluated by mtDNA 
content) and mitochondrial network distribution induced by the cytoskeleton-destabilizing 
agent Taxol, suggesting that LDL-induced migratory capabilities may indeed be strictly linked to 
mitochondrial-cytoskeleton interactions within MDA-MB-231 cells (Supplementary Figure 4).  
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4.3. Effect of LDL exposure in Taxol chronically-exposed TNBC  
 
Abnormal lipid metabolism has been reported as a metabolic adapted feature of 
chemotherapy resistant breast cancer cells and several studies show that targeting metabolism 
of tumor cells could be a promising strategy to revert Taxol-resistance in several types of cancer, 
including TNBC. 
A major number of therapeutic guidelines recommend Taxol as first-line therapy for 
treatment of metastatic breast cancer 39,42,61,62, due to its ability to suppress cancer cells 
migration and proliferation 63. In the clinic, patients with advanced breast cancer and bone 
metastasis present higher response rates after treatment with Taxol 64, evidencing  the role of 
Taxol in impairing and compromising cancer cells migration. 
We wanted to address the impact of chronic exposure to the chemotherapeutic and 
cytoskeleton-destabilizing agent Taxol in the migratory capability and mitochondrial mass of 
MDA-MB-231 cells and the impact of higher LDL environments on these parameters.  
We started by exposing two TNBC cell lines, MDA-MB-231 and MDA-MB-468, chronically to 
Taxol with the aim of establishing Taxol-resistant cell lines. There is a variety of protocols with 
different approaches to establish Taxol-resistant BC cell lines 52,65,66. The values of IC50 reported 
for different cancer cell lines are drug and time dependent and for this reason, there are some 
discrepancies between the values of different studies. We decided to expose TNBC cell lines to 
a chronic concentration of Taxol within the range of IC50 values reported for the MDA-MB-231 
and MDA-MB-468 cell lines. The reported IC50 values varies between 1 - 9 nM for MDA-MB-231 
cells and between 1,8 nM - 4 nM for MDA-MB-468 42,67–69.  
Thus, in order to establish Taxol-resistant TNBC cell lines, we exposed MDA-MB-231 and 
MDA-MB-468 chronically to 2,5 nM Taxol during 12 weeks. After this period, we evaluated the 
Taxol-sensitivity by performing a viability assay under increasing Taxol doses (Figure 9). 
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Figure 9. Cell viability of human TNBC (MDA-MB-231 and MDA-MB-468) parental and Chronic 
Exposed to Taxol (CE-Taxol) cell lines. 
To generate Taxol-resistant TNBC cell lines, MDA-MB-231 and MDA-MB-468 were exposed to a 
chronic concentration of Taxol 2,5 nM during 12 weeks. To evaluate the sensitivity to Taxol, we 
perform a viability assay with MDA-MB-231 Parental and CE-Taxol (a) and MDA-MB-468 
Parental and CE-Taxol (b) under different Taxol concentrations (0 nM, 1 nM, 2,5 nM , 5 nM, 7,5 
nM and 10 nM) during 5 days. Cell viability was measured by counting the number of viable cells 
in the fifth day using Trypan Blue exclusion test by hemocytometer counts (4 squares per well, 
n=4 each from one representative experiment). Data are presented as mean ± s.d. Statistical 
significance was determined by two-tailed Student t-test. **, P < 0.01; ***, P < 0.001. 
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Regarding MDA-MB-231 CE-Taxol cells, it should be noted that for concentrations greater 
than 5 nM, the parental MDA-MB-231 cell line exhibits significantly higher sensitivity and lower 
cell viability compared to concentrations of 1 and 2,5 nM (Figure 9a)). We could say that at the 
end of 12 weeks of chronic exposure, cells have acquired resistance to Taxol for concentrations 
that range between 5 nM and 10 nM, evidenced by their lower sensitivity and higher cell viability 
when compared to the parental cell line. Moreover, we do not observe differences in cell 
viability between untreated and Taxol treated (for any dose) MDA-MB-231 CE-Taxol cells. On 
the other hand, after 12 weeks of chronic exposure, there is no difference in the Taxol-sensitivity 
of MDA-MB-468 CE-Taxol when compared to the parental cell line, since both lines present 
significantly increased sensitivity and lower cell viability for concentrations higher than 5 nM 
(Figure 9b)), which probably means that the time of Taxol-exposure (12 weeks) was not enough 
to induce resistance or to decrease sensitivity in this cell line. 
Overall, we can conclude that after 12 weeks exposure, we were able to establish a MDA-
MB-231 cell line with acquired resistance to Taxol, as determined by its lower sensitivity to the 
drug for concentrations between 5 and 10 nM, but still displaying sensitivity at 10 nM, therefore 
we decided to designate as Taxol chronic-exposed (CE) MDA-MB-231 rather than Taxol-resistant 
cells. 
Next, we analyzed the impact of Taxol-chronic exposure in the parameters of TNBC cell 
lines aggressiveness (migration and proliferation) and mitochondrial mass and whether LDL-
enriched environments could modulate these parameters. For that, we exposed CE-Taxol MDA-
MB-231 cells to LDL, Taxol (2,5 nM; the dose used for the chronic exposure) and both in 
combination and performed the wound-healing assay, followed by quantification of 
mitochondrial mass and additionally performed a proliferation assay under the same conditions 
(Figure 10). Additionally, in order to address if the effect produced by LDL exposure was similar 
between parental and chronically-exposed cell lines, we also performed a wound-healing assay, 
followed by quantification of mitochondrial mass, as well as a proliferation assay upon control 
and LDL conditions (Figure 11).  
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Figure 10. Effect of LDL in the migratory, proliferation and mitochondrial mass of MDA-MB-
231 CE-Taxol cells. 
a) Migratory capacity represented as percentage of wound closure at 16h by wound 
healing assay (n = 4 each from one representative experiment); b) Representative 
images of wound closure at 0h and 16h by optical microscopy (4x objective); c) Relative 
mtDNA content based on the mitochondrial ND1 gene relative to the nuclear B2MG 
gene (n =  3 each) d) Proliferation assay by cell count ratio. The number of viable cells 
was counted using Trypan Blue exclusion test by hemocytometer counts (4 squares per 
well, n=4 each). Data are presented as mean ± s.d. Statistical significance was 
determined by two-tailed Student t-test. **, P < 0.01; ***, P < 0.001. 
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Figure 11. Analysis of the effect of LDL between MDA-MB-231 Parental and MDA-MB-231 
chronic exposed to Taxol 2,5 nM (MDA-MB-231 CE-Taxol). 
a)  Migratory capacity represented as percentage of wound closure at 16h by wound 
healing assay (Control, LDL, n = 4, each); b) Proliferation assay by cell count ratio where 
the number of viable cells was counted in the second day using Trypan Blue exclusion 
test by hemocytometer counts (Control, LDL, 4 squares per well, n=4 each ); c) Relative 
mtDNA content based on the mitochondrial ND1 gene relative to the nuclear B2MG 
gene in LDL-exposed group relative to the control group (n=3/4). Data are presented as 
mean ± s.d. Statistical significance was determined by two-tailed Student t-test. *, P < 
0,05 **, P < 0.01; ***, P < 0.001. 
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Similarly, to what occurs with the MDA-MB-231 parental line (Figure 7a) and b)), LDL 
significantly increases the migratory (Figure 10a) and 10b)) of MDA-MB-231 CE-Taxol cells and 
the same trend is observed for the mitochondrial mass (Figure 10c)). Additionally, LDL exposure 
also induced a significant increase in proliferation capacity in MDA-MB-231 CE-Taxol cells (Figure 
10d)).  Therefore, we comparing both parental and Taxol chronic-exposed MDA-MB-231 cells, 
we detected no significant differences in the LDL induced phenotype (Figure 11). In other words, 
the values for increased cell migration and proliferation (Figure 11a) and c)) and increased 
mitochondrial mass (Figure 11b)) are similar for both control and LDL conditions in MDA-MB-
231 parental and MDA-MB-231 CE-Taxol.  
We also could observe that, contrary to what was observed upon acute exposure of 
Taxol 20 nM (Figure 7a) and 7b)) in parental MDA-MB-231 cells, treatment with a low dose of 
Taxol does not affect the migratory capacity or mitochondrial mass of MDA-MB-231 CE-Taxol 
(Figure 10a) and 10b)), resembling the control levels. Also, low Taxol doses do not interfere with 
the proliferation capacity of MDA-MB-231 CE-Taxol (Figure 10d)). Thus, even in the presence of 
a low dose of cytoskeleton-destabilizing agent, Taxol, MDA-MB-231 CE-Taxol cells do not exhibit 
defects in the migratory and proliferation capacity. 
Regarding MDA-MB-231 CE-Taxol cells, we observe that the simultaneous addition of 
Taxol and LDL does not cause a very marked increase over the Taxol condition, except for the 
migratory capacity in which a slight but significant increase is observed upon combined 
treatment, although it did not reach the increase percentage displayed by LDL-treated MDA-
MB-231 CE-Taxol cells. 
 Therefore, preliminary results suggest that MDA-MB-231 CE-Taxol has no defects on the 
migratory and proliferative capacity nor in mitochondrial mass and the parameters induced by 
LDL exposure in MDA-MB-231 cells are largely retained in MDA-MB-231 with acquired resistance 
to Taxol except for the migratory capability. However, in MDA-MB-231 CE-Taxol, LDL was not 
able to fully recover the defect produced by a low dose of Taxol in the migratory capacity, 
contrary to what had been observed with the addition of an acute dose of Taxol combined with 
LDL in untreated MDA-MB-231 cells (Figure 7a) and b)). Moreover, we can preliminarily 
conclude that chronic exposure to Taxol seems to produce a permanent defect in cell motility 
that cannot be rescued by LDL exposure. 
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5. Discussion 
 
As observed in other types of cancer, TNBC cells are able to reprogram their cellular 
metabolism (including lipid metabolism) in communication with the surrounding 
microenvironment, in order to successfully met the requirements that sustain cell growth, 
proliferation and invasion capabilities 16,19–21. 
A major focus of our laboratory is to study the impact of the tumor micro- and macro- 
environment, especially the role of lipids availability, in the acquisition of aggressive tumors 
phenotypes in breast cancer. In particular, it was recently shown that LDL plays a key role in 
TNBC growth and proliferation 27,29. More recently, it was observed that LDL-exposed TNBC cells 
present increased mitochondrial mass as determined by MitoTracker staining, quantification of 
mtDNA content and electron microscopy (Nóbrega-Pereira et al., unpublished). Despite this 
information, the exact nature of mitochondrial network adaptations induced by LDL-exposure 
and how it affects the acquisition of an aggressiveness migratory phenotype remains unclear. 
In this context, one of the aims of this project was to understand how LDL-exposure impacts 
the mitochondrial phenotype in TNBC migrating cells, including mitochondrial mass and 
mitochondrial network distribution and morphology. 
LDL-exposure increases cell migration and proliferation in TNBC cells 19, which are 
accompanied by changes in mitochondrial mass and arrangements in mitochondrial network, as 
suggested by our results. Moreover, our data suggest that changes in mitochondrial mass 
observed during cell migration may be specific from lipid-enriched environments, since LPA-
induced migration did not affected mitochondrial mass contrary to what was observed in LDL 
and PA-exposed migrating TNBC cells. This observation is not surprising since one study reported 
an association between cancer aggressiveness (such as increased cell proliferation, migration 
and metastasis) and expression of a scavenger receptor, CD36, which may uptake LDL and 
different types of fatty acids.70 Nevertheless, the exact molecular nature of the mechanisms 
present in both LDL and PA that promotes the effects in MDA-MB-231 cells was not assessed in 
this study. 
Mitochondria are versatile organelles capable of modulate their shape and size depending 
on the cell requirements and in interaction with the micro- and macro- environment 33,34. 
Depending on the cell type and the exact mitochondria program most active in a certain 
moment, mitochondria can exhibit different network arrangements 56. In this study, we 
observed two different arrangements of mitochondrial network: mitochondrial aggregates 
(clusters) located preferentially at only one side of the nucleus – perinuclear mitochondria - and 
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long filaments, located randomly unilaterally or bilaterally around the nucleus and distributed 
throughout the whole cell – filamentous mitochondria.  
In LDL-exposed cells, MDA-MB-231 cells exhibit both phenotypes. The presence of MDA-
MB-231 cells at the front of the wound displaying a filamentous arrangement could be 
associated with the increased migratory capacity observed in this condition. In line with these 
observations, it was shown by others that in migrating TNBC and PC3 (human prostate cancer) 
cells, the presence of mitochondria between the nucleus and the leading edge of the cell is 
associated with higher velocity of migration and increased directional persistence. This study 
raises the possibility that a great mitochondrial density at the leading edge of the cell is essential 
in order to sustain the occurrence of high energetic processes, including actin polymerization 
and the formation of new focal adhesions, which are essential for cell motility36. Another recent 
study revealed that increased mitochondria fission is required for the accumulation of 
mitochondria in the lamellipodia region of migrating TNBC cells, a key step for cell motility and 
BC cells migration and invasion 31. This study evidences the importance of mitochondrial 
network arrangement throughout the whole cell, especially at the leading edge, to enhance 
metastatic potential in tumor cells. Additionally, it was reported that PI3K-inhibitors induce 
signaling reprogramming in tumor cells and as a consequence, mitochondria are moved to the 
leading edge of the cell where important processes for cancer progression are occurring, such 
as lamellipodia and focal adhesion formation and random cell motility 71.  
We went further to study mitochondrial network morphology using ImageJ software and 
our quantitative analysis showed that LDL exposure in MDA-MB-231 cells increases 
mitochondria number, size and interconnectivity, but not elongation. 
Overall, our results suggest that LDL could regulate the shape and the mitochondrial 
network distribution, inducing a more filamentous arrangement, which may be implicated in the 
increased migratory capacity induced by LDL-exposure in TNBC cells.  Moreover, this 
aggressiveness induced by LDL in MDA-MB-231 cells is accompanied by changes in 
mitochondrial morphology, namely increased mitochondria number, size and interconnectivity. 
We hypothesized if the alterations mentioned above could be due to a differential 
interaction between mitochondria and the cytoskeleton in TNBC migrating cells upon LDL-
exposure. In order to address this question, we decided to use Taxol, a widely used 
chemotherapeutic and cytoskeleton-destabilizing drug, to interfere and disrupt cytoskeleton 
dynamics.  
Our data show that exposure to an acute dose of Taxol adversely impacts the migration of 
MDA-MB-231 cells, where we could observe a decrease in mitochondrial mass (as determined 
by evaluation of mtDNA content) and a disruption in the mitochondrial network, evidencing the 
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key role of mitochondrial-cytoskeleton interaction during MDA-MB-231 migration. Interestingly, 
LDL seems to be capable to reverse the defects caused by Taxol-exposure, namely migratory 
capacity, mitochondrial mass and mitochondrial network distribution. 
Mitochondria are able to readapt their dynamics and distribution in a way that favors cell 
the most, both under physiological and pathological conditions including cancer. Indeed, in 
TNBC cells, mitochondria change from a perinuclear distribution to a filamentous arrangement 
distributed all over the leading edge of the cells during the process of lamellipodia formation 
and in close contact to F-actin filaments. In agreement, we also observe increase lamellipodia 
formation in LDL-exposed TNBC migrating cells (Supplementary Figure 5). This process is 
essential for cancer invasion and progression and requires a great number of fragmented 
mitochondria 31.  
Anesti and Scorrano reviewed the importance of cytoskeletal proteins in modulating the 
shape and distribution of the mitochondrial network across the cell 34, for instance ablation of 
certain cytoskeleton proteins could be accompanied by a specific rearrangement of the 
mitochondrial network that leads to cell apoptosis 57. This data enhanced the essential role of 
the interaction between mitochondria and cytoskeleton to the cell. Since tumor cells are 
permanently exposed to high levels of cellular stress, the cytoskeleton-mitochondria interaction 
will be crucial for malignant cells to be able to adapt to different environments that tumor cells 
encounter, and rearrange the mitochondrial network in a way that favors tumor progression. A 
very recent study in HeLa cells, revealed that Miro1/2, both outer mitochondrial membrane 
proteins, directly bind to myosin XIX (Myo19) and downregulation of Myo19, leads to 
perinuclear clustering of mitochondria 58 . 
During cancer cells migration and invasion, fragmented mitochondria appear to be a 
requirement for efficient mitochondria relocation to specific cell sites. Organelles transport 
within the cells is a process majority mediated by cytoskeleton motor proteins; therefore, 
mitochondria fragmentation could be a prerequisite for better interaction with cytoskeletal 
proteins, which in turn mobilize mitochondria to cell sites with high-energy demand, including 
lamellipodia formation areas. 
Our mitochondrial morphometrics analysis revealed that MDA-MB-231 exhibit highly 
fragmented mitochondria network (more fission). Additionally, in migrating TNBC cells, LDL 
exposure restored the migratory capacity, as well as the mitochondrial mass and network 
distribution disturbance induced by the cytoskeleton-destabilizing drug Taxol. Therefore, LDL-
induced aggressiveness phenotype, namely increased migratory capacity, may rely in specific 
mitochondrial-cytoskeleton interactions. 
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Since reprogramming cell metabolism is one of the most common adaptations displayed by 
chemotherapy resistant cancer cells, in the last aim of this project we decided to explore the 
impact of chronic-exposure to the chemotherapeutic agent Taxol in the migratory capacity and 
mitochondrial mass of TNBC cells and how exposure to LDL environments could affect these 
parameters. 
In hepatocellular carcinoma (HCC), upregulation of STAR, an essential protein that regulates 
cholesterol import to mitochondria, contributes to higher levels of mitochondrial cholesterol 
content and decreased sensitivity to chemotherapeutic agents. Additionally, the same study 
demonstrated that knockdown of STAR resensitized HCC cells to chemotherapy72. Some studies 
report the use of statins as anti-cancer drugs and their combined use with chemotherapeutic 
agents exhibit synergistic effects, reducing tumor growth and proliferation73, as well as reduce 
the development of multidrug resistance74. In breast cancer, the use of statins is associated with 
lower incidence of relapses in patients diagnosed at early stage75 and with lower acquired 
resistance to endocrine therapy in patients with ER+ breast cancer76. 
Although clinical studies show a therapeutic benefit in the combination of statins and 
chemotherapeutic drugs, there is no clear evidence about the molecular mechanisms underlying 
the possible link between hypercholesterolemia and resistance to chemotherapy. In this part of 
the study, we wanted to address how chronic-exposed TNBC cells react to high cholesterol 
environments, namely in terms of migration and proliferation capacity and mitochondrial mass. 
Our results show that MDA-MB-231 CE-Taxol cells present no defects in migration and 
proliferation capacity, or in the mitochondrial mass, even in the presence of a low dose of Taxol, 
when compared to untreated (control) MDA-MB-231 CE-Taxol cells. Moreover, we could 
observe that parental MDA-MB-231 and MDA-MB-231 CE-Taxol cells, both exhibit similar 
responses to LDL-exposure in terms of proliferation and migration capacity and mitochondrial 
mass. 
Since Taxol chronic-exposed MDA-MB-231 cells present unaltered proliferation and 
migration capability and unchanged mitochondrial mass, we can preliminary conclude that 
acquired resistance to Taxol could be (somehow) dependent on mitochondrial activity. 
It was reported in lung adenocarcinoma that cells resistant to cisplatin, a chemotherapeutic 
agent, exhibit increased mitochondrial membrane potential (MMPs), which is accompanied with 
increased migratory and invasive capacity 77. In line with our observations, this study suggests 
that adaptations in mitochondria could be a determinant step to tumor cells acquire drug-
resistance.  
In another study, evaluation of mitochondrial mass was used as a biomarker of 
chemotherapy sensitivity in HeLa cells. Levels of apoptotic proteins are modulated by the 
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number of mitochondria and increased mitochondrial mass is associated with more 
susceptibility to the apoptotic machinery, which in turn induces greater sensitivity to 
chemotherapeutic agents in these cells 78. Interestingly (and in line with our observations), in 
MDA-MB-231 and MCF-7 cells, a TNBC and a Luminal A breast cancer cell lines, respectively, it 
was shown that increased mitochondrial mass is associated with a stem-like phenotype, which 
in turn induces less sensitivity to Taxol79. In general, both studies have demonstrated that 
depending on the type of cancer and the stage of the disease, chemotherapy resistance could 
be accompanied by adaptations in mitochondria, which in turn may be determinant for the drug-
resistant phenotype. 
Exposure of MDA-MB-231 CE-Taxol to low doses of Taxol, did not produced major changes 
in proliferation, migration and mitochondrial mass compared to MDA-MB-231 CE-Taxol 
untreated. However, when combined to a low dose of Taxol, LDL interestingly did not 
significantly alter this fact (except for the migratory capacity, where we could observe a slight 
but significant increase when compared to MDA-MB-231 CE-Taxol untreated and treated with 
Taxol 2,5 nM).  
Therefore, these preliminary data suggest that, in spite of mtDNA levels between MDA-MB-
231 CE-Taxol exposed to LDL or MDA-MB-231 CE-Taxol exposed to LDL and Taxol remain similar, 
low doses of Taxol treatment in MDA-MB-231 CE-Taxol cells can compromise the cytoskeleton 
dynamics that, in turn, do not allow LDL treatment to rescue the migratory capacity. 
Taken together, this study provides new highlights about the role of the aggressiveness 
phenotype induced by LDL exposure.  
Firstly, LDL-induced increased migration capability is accompanied by changes in several 
mitochondrial morphology parameters, as well as network arrangement, which in turn seems to 
be dependent on specific mitochondria-cytoskeleton interactions. Thus, targeting mitochondria-
cytoskeleton interaction could be a promising strategy to disrupt tumor cells invasion and 
metastasis. However, further studies are necessary to determine the exact molecular 
mechanisms underlying this interaction. 
Regarding Taxol-resistance, our preliminary data suggest that acquired resistance to Taxol 
(or less sensitivity) could be somehow dependent on the mitochondrial activity. Moreover, our 
preliminary results may unravel the role of LDL in the context of chemotherapy resistance, which 
it is not a much elucidated research field. After Taxol-treatment, LDL is able to severely increase 
cell proliferation and migration, enhancing the metastatic and invasive potential of these cells, 
whereas during Taxol treatment this effect is not so pronounced. In other words, during Taxol 
treatment the aggressiveness features induced by LDL exposure are attenuated in some manner. 
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However, after treatment with Taxol, tumor cells in the presence of a LDL-enriched environment 
are able to recuperate their metastatic and proliferative potential. 
Overall, these findings provide novel ideas about the role of LDL in cancer aggressiveness 
that could be extremely important in the clinic, more precisely in terms of acquired resistant to 
chemotherapy. Moreover, LDL appears once again as an interesting candidate to target and, 
consequently, to disrupt cancer progression.  
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7. Supplementary Data 
 
 
Supplementary Figure 1. Effect of PA in the migratory capacity and mitochondrial mass of 
MDA-MB-231 cells. 
a) Migratory capacity represented as percentage of wound closure at 24h by wound 
healing assay (n=3); b) Representative images of wound closure at 0h and 24h by 
optical microscopy (4x objective); c) Relative mtDNA content based on the 
mitochondrial ND1 gene relative to the nuclear gene B2MG in PA-exposed group 
relative to the control group (n =4). Data are presented as mean ± s.d. Statistical 
significance was determined by two-tailed Student t-test. ***, P < 0.001. 
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Supplementary Figure 2 Effect of LDL in mitochondrial morphometrics (size and elongation) in 
MCF-7 and MDA-MB-231 migrating cells. 
Quantification of mitochondrial morphometrics (size and elongation) of MCF-7, control and LDL-
exposed MDA-MB-231 migrating cells (n ≥ 18 cells). a) Mean size of mitochondria; b) Mean 
elongation of mitochondria. Data are presented as mean ± s.d. Statistical significance was 
determined by two-tailed Student t-test. **, P < 0.01; ***, P < 0.001. 
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Supplementary Figure 3. Analysis of mitochondrial mass across several breast cancer cell lines 
(Luminal A – MCF-7; Luminal B – BT-474; Triple-Negative – MDA-MB-468 and MDA-MB-231). 
a)  Mitochondrial mass represented as mean fluorescence intensity (MFI) of MitoTracker 
Deep Red relative to the MCF-7 group (n = 5/6 from two independent experiments b) 
Relative mtDNA content based on the mitochondrial ND1 gene relative to the nuclear 
B2MG gene relative to MCF-7 group (n= 5/6 from two independent experiments). Data 
are presented as mean ± s.d. Statistical significance was determined by two-tailed 
Student t-test. *, P < 0.05; ***, P < 0.001. 
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Supplementary Figure 4. Taxol-induced phenotype is restored by LDL and is dependent on 
mitochondria-cytoskeleton interactions. 
Representative epifluorescence images of Control (upper panel), LDL (second panel), Taxol 20 
nM (third panel) and Taxol 20 nM+LDL exposed MDA-MB-231 cells (lower panel). MDA-MB-231 
cells are stained with α-tubulin in green, HSP60 (mitochondria) in red and DAPI (nuclei) in dark 
blue. The dashed white line represents the wound front edge. Images were acquired with a 40x 
oil objective. Scale bar 10 μm. 
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Supplementary Figure 5. LDL-exposed MDA-MB-231 cells present increased lamellipodia 
formation. 
Representative confocal images of control (upper panel) and LDL-exposed (lower panel) MDA-
MB-231 cells transfected with MitoYFP and stained with Phalloidin-647 (F-actin) and DAPI 
(nuclei). Images were acquired with a 63x oil objective. Scale bar equals 10 μm.  
 
